第八版美国癌症联合委员会食管癌临床分期分组的验证。
Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer.
机构信息
Surgery Department, Swiss Cancer Institute, Cham, 63302, Switzerland.
Department of General, Visceral & Transplant Surgery, University of Heidelberg, Heidelberg, 691175, Germany.
出版信息
Future Oncol. 2018 Jan;14(1):65-75. doi: 10.2217/fon-2017-0376. Epub 2017 Dec 13.
AIM
To validate the American Joint Committee on Cancer (AJCC) clinical staging system for esophageal cancer using Surveillance, Epidemiology and End Results database.
METHODS
Cancer-specific survival analyses for clinically-staged patients with esophageal cancer according to both seventh and eighth editions were conducted through Kaplan-Meier analysis.
RESULTS
For cancer-specific survival according to both seventh and eighth clinical systems, p-values for pairwise comparisons were nonsignificant in many comparisons. C-index for adenocarcinoma was: 0.671 according to the seventh AJCC and 0.671 according to the clinical eighth AJCC. C-index for squamous cell carcinoma according to the seventh AJCC was: 0.634 and 0.643 according to clinical eighth AJCC.
CONCLUSION
Minimal improvement was achieved by the eighth clinical AJCC staging system for esophageal cancer.
目的
使用监测、流行病学和最终结果数据库验证美国癌症联合委员会（AJCC）食管癌临床分期系统。
方法
根据第七版和第八版，对食管癌临床分期患者进行癌症特异性生存分析，采用 Kaplan-Meier 分析。
结果
根据第七版和第八版临床系统的癌症特异性生存，许多比较的两两比较 p 值均无统计学意义。腺癌的 C 指数为：第七版 AJCC 为 0.671，第八版 AJCC 为 0.671。第七版 AJCC 鳞状细胞癌的 C 指数为：0.634 和 0.643 根据第八版临床 AJCC。
结论
第八版临床 AJCC 食管癌分期系统仅略有改善。
Zotero 插件